LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Vera Therapeutics (VERA – Research Report) today and set a price target of $70.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Rami Katkhuda has given his Buy rating due to a combination of factors influencing the outlook for Vera Therapeutics. Despite recent market reactions to Otsuka’s update regarding sibeprenlimab, Katkhuda believes the negative sentiment may be excessive. The uncertainty surrounding the FDA’s approval of at-home administration for sibeprenlimab and the necessity of professional supervision in clinical trials are pivotal considerations.
Additionally, Vera’s ongoing Phase III ORIGIN 3 study for atacicept, which has shown promising Phase II results, positions the company favorably. The atacicept treatment’s long-term efficacy data and its unique status as a self-administered injection offer a significant competitive edge. Given the potential for atacicept to address IgAN effectively and the anticipated large market opportunity, Katkhuda views Vera Therapeutics as a strong candidate for growth, warranting a Buy recommendation.
Katkhuda covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Disc Medicine, and VYNE Therapeutics. According to TipRanks, Katkhuda has an average return of 26.6% and a 45.45% success rate on recommended stocks.
In another report released on February 14, Wells Fargo also maintained a Buy rating on the stock with a $70.00 price target.